FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims - Eli Lilly (NYSE:LLY)

FDA Warns Companies Against False and Misleading Drug Ads

Federal regulators sent dozens of letters to companies in September warning them that their advertisements for drugs are misleading and could lead to repercussions unless fixed. The Food and Drug Administration on Sept. 16 released 65 letters it sent on Sept. 9 to companies, including Eli Lilly and Novo Nordisk. President Donald Trump signed a memorandum that day directing officials to enforce existing rules surrounding direct-to-consumer advert…

Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk disclosure and safety messaging.

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims - Eli Lilly (NYSE:LLY)

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.